Hydroxyurea induces bystander cytotoxicity in cocultures of herpes simplex virus thymidine kinase-expressing and nonexpressing HeLa cells incubated with ganciclovir

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3845-3851

  Gentry, Brian G ^a   Boucher, Paul D ^a   Shewach, Donna S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; HYDROXYUREA; THYMIDINE KINASE;

ARTICLE; BYSTANDER EFFECT; CELL POPULATION; COCULTURE; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; HELA CELL; HERPES SIMPLEX VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COCULTURE TECHNIQUES; DEOXYGUANINE NUCLEOTIDES; DRUG SYNERGISM; GANCICLOVIR; GENE THERAPY; HELA CELLS; HUMANS; HYDROXYUREA; NUCLEOTIDES; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 33645750933     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3660     Document Type: Article

References (45)

1. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994;1:279-87.
2. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81.
3. Yazama K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg 2002;26:783-9.
4. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2.
5. Rubsam LZ, Davidson BL, Shewach DS. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res 1998;58:3873-82.
6. Cheng Y, Grill SP, Butschman GE, Nakayama K, Bastow KF. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine, a new anti-herpes compound, in herpes simplex virus-infected cells. J Biol Chem 1983;258:12460-4.
7. Boehme RE. Phosphorylation of the antiviral percursor 9-(1,3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isozymes. J Biol Chem 1984;259:12346-9.
8. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2- propoxymethyl)-guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993;268:6332-7.
9. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2-deoxyguanosine 5′-triphosphate analogs. J Biol Chem 1989;264:19039-44.
10. Reid R, Mar E, Huang E, Topal MD. Insertion and extension of acyclic, dideoxy, and Ara nucleotides by herpesviridae, human α and β polymerases. J Biol Chem 1988;263:3898-904.
11. Smee DF, Boehme RE, Chernow M, Binko BP, Matthews TR. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)- guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol 1985;34:1049-56.
12. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Nat Cancer Inst 1997;89:21-39.
13. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997;33:1005-16.
14. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83.
15. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001;187:22-36.
16. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997;8:1825-35.
17. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997;4:244-51.
18. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993;4:725-31.
19. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 1996;93:1831-5.
20. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000;60:3989-99.
21. Imaizumi K, Hasegawa Y, Kawabe T, et al. Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines. Am J Respir Cell Mol Biol 1998;18:205-12.
22. Asklund T, Appelskog IB, Ammerpohl O, et al. Gap junction-mediated bystander effect if primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res 2003;284:185-95.
23. Boucher PD, Ruch RJ, Shewach DS. Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther 1998;9:801-14.
24. Rubsam LZ, Boucher PD, Murphy PJ, KuKuruga M, Shewach DS. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res 1999;59:669-75.
25. Ruch RJ. The role of gap junctional intercellular communication in neoplasia. Ann Clin Lab Sci 1994;24:216-31.
26. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996;3:85-92.
27. Dilber MS, Abedi MR, Christensson B, et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997;57:1523-8.
28. Sanson M, Marcaud V, Robin E, Valery C, Sturtz F, Zale B. Connexin 43-mediated bystander effect in two rat glioma cell models. Cancer Gene Ther 2002;9:149-55.
29. Marconi P, Tamura M, Moriuchi S, et al. Connexin 43-enhanced suicide gene therapy using herpes viral vectors. Mol Ther 2000;1:71-81.
30. Burrows FJ, Gore M, Smiley WR, et al. Purified herpes simplex virus thymidine kinase retroviral particles. III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther 2002;9:87-95.
31. Cirenei N, Colombo BM, Mesnil M, Benedetti S, Yamasaki H, Finocchiaro G. In vitro and in vivo effects of retrovirus-mediated transfer of connexin 43 gene in malignant gliomas: consequences for HSVtk/GCV anticancer gene therapy. Gene Ther 1998;5:1221-6.
32. Robe PA, Jolois O, N'Guyen M, et al. Modulation of the HSV-Tk/ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication. Int J Oncol 2004;25:187-92.
33. Ammerpohl O, Thormeyer D, Khan Z, et al. HDACi phenybutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun 2004;324:8-14.
34. Park JY, Elshami AA, Amin K, Rizk N, Kaiser LR, Albelda SM. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Ther 1997;4:909-17.
35. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther 1998;9:2385-91.
36. Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes simplex virus thymidine kinase/ ganciclovir-mediated cytotoxicity by hydroxyurea. Cancer Res 2000;60:1631-6.
37. Boucher PD, Shewach DS. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol Ther 2005;12:1064-71.
38. Boucher PD, Ostruszka LJ, Murphy PJM, Shewach DS. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ ganciclovir gene therapy. Gene Ther 2002;9:1023-30.
39. Mesnil M, Piccoli C, Yamasaki H. A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res 1997;57:2929-32.
40. Tanaka T, Yamasaki H, Mesnil M. Induction of a bystander effect in HeLa cells by using a bigenic vector carrying viral thymidine kinase and connexin 32 genes. Mol Carcinog 2001;30:176-80.
41. Gentry BG, Im M, Boucher PD, Ruch RJ, Shewach DS. GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity. Gene Ther 2005;12:1033-41.
42. Elfgang C, Eckert R, Lichtenberg-Frate H, et al. Specific permeability and selective formation of gap junction channels in connexin-transfected HeLa cells. J Cell Biol 1995;129:805-17.
43. Oh DJ, Lee GM, Francis K, Palsson BO. Phototoxicity of the fluorescent membrane dyes PKH2 and PKH26 on the human hematopoietic KG1a progenitor cell line. Cytometry 1999;36:312-8.
44. Tanaka T, Yamasaki H, Mesnil M. Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro. Int J Cancer 2001;91:538-42.
45. Wygoda MR, Wilson MR, Davis MA, Trosko JE, Rehemtulla A, Lawrence TS. Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells. Cancer Res 1997;57:1699-703.